PFW Advisors LLC Invests $329,000 in Novo Nordisk A/S (NYSE:NVO)

PFW Advisors LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 3,824 shares of the company’s stock, valued at approximately $329,000.

Several other institutional investors have also recently added to or reduced their stakes in NVO. Natixis Advisors LLC grew its position in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC raised its position in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares during the period. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $86,000. Zions Bancorporation N.A. boosted its position in Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Novo Nordisk A/S by 14.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after buying an additional 37,346 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.1 %

Shares of NYSE:NVO traded down $1.83 during mid-day trading on Monday, hitting $84.43. The stock had a trading volume of 7,283,059 shares, compared to its average volume of 7,401,729. The company has a market cap of $378.88 billion, a PE ratio of 27.32, a P/E/G ratio of 1.37 and a beta of 0.45. The company’s 50 day moving average is $100.35 and its 200-day moving average is $119.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15.

Wall Street Analyst Weigh In

NVO has been the subject of several analyst reports. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.